NASDAQ · ACHV
Achieve Life Sciences, Inc.
$7.19+$0.34 (+4.96%)
Achieve Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.78% below the high.
Loading market information…
NASDAQ · PRQR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ProQR Therapeutics N.V.’s quoted price sits in the lower half of its reported 52-week range, 48.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ProQR Therapeutics N.V.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.11. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ProQR Therapeutics N.V.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.11-22.22% vs estimate | $4.95M+3.1% vs estimate |
|---|
| Q4 2024 | Mar 13, 2025 | -$0.100.0% vs estimate | $4.46M-18.1% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.11+8.33% vs estimate | $4.21M-39.81% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $3.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.19+$0.34 (+4.96%)
Achieve Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.78% below the high.
$2.93-$0.02 (-0.68%)
Editas Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.63% below the high.
$1.25-$0.05 (-3.85%)
Allogene Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.97% below the high.
$6.63+$0.40 (+6.42%)
Capricor Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.58% below the high.
$3.85-$0.50 (-11.49%)
Zura Bio Limited’s quoted price sits in the lower half of its reported 52-week range, 48.25% below the high.
$12.15+$0.08 (+0.66%)
Arcturus Therapeutics Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.35% below the high.
$4.05+$0.05 (+1.25%)
Vanda Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.26% below the high.
$4.40-$0.44 (-9.09%)
Entrada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.25% below the high.
